For the past 40 years, beta‐blockers have been widely used in cardiovascular medicine,
reducing morbidity as well as mortality. Beta‐blockers are currently used in a number of …

Beta-blockers are a heterogeneous group of antihypertensive agents. What they have in
common is competitive antagonistic action on beta-adrenoreceptors (B1, B2 and B3). They …

Beta adrenoceptor blocking drugs are all competitive inhibitors of the beta receptor although
they may or may not possess, beta 1-(cardio) selectivity, intrinsic sympathomimetic activity …

Use of non-selective [beta]-blockers: Non-selective [beta]-blockers reduce blood pressure by
reducing cardiac output. They have a proven record of efficacy, alone or in combination with …

For more than 3 decades, beta-blockers have been widely used in the treatment of
hypertension and are still recommended as first-line agents by national and international …

β-Blockers are widely used in cardiovascular medicine. In patients with hypertension, β-
blockers show beneficial effects on clinical end points of stroke and coronary heart disease …

We conducted a series of studies aimed at investigating the effect of beta-blockers on
exercise physiology. On the basis of these and other existing studies, it is possible to draw …

The role of β-adrenoceptor antagonists (β-blockers) in cardiovascular therapy has been
subject to diverse trends and changes over the decades. With the advent of a wide variety of …

[beta]-Adrenergic-blocking drugs (BABs) have a firm place in the therapy of cardiovascular
conditions including angina and hypertension. Although all BABs are competitive inhibitors …

Cardioselective β-blockade is generally well tolerated in practice and contraindications to
this therapy are uncommon. β-blockers are a diverse therapeutic class, and their individual …